The effects of rosiglitazone [Avandia] on cognition in patients with MCI [mild cognitive impairment]

Trial Profile

The effects of rosiglitazone [Avandia] on cognition in patients with MCI [mild cognitive impairment]

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2016

At a glance

  • Drugs Rosiglitazone (Primary)
  • Indications Mild cognitive impairment
  • Focus Biomarker; Therapeutic Use
  • Acronyms RECALL
  • Most Recent Events

    • 04 Aug 2011 Planned end date changed from 1 Jul 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.
    • 29 Jan 2009 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
    • 14 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top